Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

VolitionRx Limited Full Fiscal Year 2023 Financial Results and Business Update

Monday, March 25, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: VolitionRx Limited reported its financial results for the fiscal year 2023, highlighting significant achievements and future plans. CEO Cameron Reynolds provided insights into the company's performance, while CFO Terig Hughes detailed financial updates. The launch of Nu.Q® Vet in Japan and ongoing partnerships in various countries were also discussed, indicating a positive trajectory for the company.
Price reaction · baseline $14.4 (2024-03-25 close) · hit after-hours · 1 other VNRX headline(s) in the window, move may be shared
day 0 close
+4.1%
day 1
+3.2%
day 3
+7.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Positive financial results for fiscal year 2023.
  • Successful launch of Nu.Q® Vet in Japan.
  • Expansion of partnerships in multiple countries.

Full Press Release Details

A short video to accompany the full fiscal year 2023 results for Volition with Group Chief Executive Officer, Cameron Reynolds, and members of the Executive Team.
• an update from Volition President and Group Chief Executive Officer, Cameron Reynolds
• a financial update from Terig Hughes, Volition Group Chief Financial Officer
• an update on Nu.Q ® Vet from Dr Tom Butera Chief Executive Officer at Volition Veterinary, following the recent launch in Japan with Fujifilm Vet Systems, as well as updates on current partners, and launches in the U.S., U.K. and Ireland, Portugal, Taiwan, Italy, and more.
• an overview of 2023 and a look ahead to 2024 from Dr. Andy Retter, Volition Chief Medical Officer

Related Articles

• Press Releases VolitionRx Announces Collaboration with Sysmex
• Press Releases VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring

VolitionRx Announces Collaboration with Sysmex

VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What were the financial results for VolitionRx in 2023?

VolitionRx reported positive financial results for the fiscal year 2023.

What updates were shared by CEO Cameron Reynolds?

Cameron Reynolds provided insights into the company's performance and future plans.

What is Nu.Q® Vet and where was it launched?

Nu.Q® Vet is a product launched in Japan, in collaboration with Fujifilm Vet Systems.

Which countries are involved in VolitionRx's partnerships?

Partnerships are ongoing in the U.S., U.K., Ireland, Portugal, Taiwan, and Italy.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare VolitionRx Nu.Q Vet Cameron Reynolds financial update 2023 results
Last updated: Mar 25, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk